KR20220038818A - 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 - Google Patents

15-hepe를 포함하는 조성물 및 이를 사용하는 방법 Download PDF

Info

Publication number
KR20220038818A
KR20220038818A KR1020227008483A KR20227008483A KR20220038818A KR 20220038818 A KR20220038818 A KR 20220038818A KR 1020227008483 A KR1020227008483 A KR 1020227008483A KR 20227008483 A KR20227008483 A KR 20227008483A KR 20220038818 A KR20220038818 A KR 20220038818A
Authority
KR
South Korea
Prior art keywords
hepe
pharmaceutical composition
subject
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227008483A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 코플랜
존 클리맥스
Original Assignee
애피뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애피뮨 리미티드 filed Critical 애피뮨 리미티드
Priority to KR1020237010220A priority Critical patent/KR20230047501A/ko
Publication of KR20220038818A publication Critical patent/KR20220038818A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227008483A 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 Ceased KR20220038818A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237010220A KR20230047501A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562269280P 2015-12-18 2015-12-18
US62/269,280 2015-12-18
KR1020207013456A KR20200055154A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
PCT/IB2016/001878 WO2017103671A1 (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207013456A Division KR20200055154A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010220A Division KR20230047501A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Publications (1)

Publication Number Publication Date
KR20220038818A true KR20220038818A (ko) 2022-03-29

Family

ID=57995240

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020207013456A Ceased KR20200055154A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
KR1020257027779A Pending KR20250130433A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
KR1020237010220A Ceased KR20230047501A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
KR1020187020457A Ceased KR20180094516A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
KR1020247011532A Ceased KR20240052856A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
KR1020227008483A Ceased KR20220038818A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Family Applications Before (5)

Application Number Title Priority Date Filing Date
KR1020207013456A Ceased KR20200055154A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
KR1020257027779A Pending KR20250130433A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
KR1020237010220A Ceased KR20230047501A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
KR1020187020457A Ceased KR20180094516A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
KR1020247011532A Ceased KR20240052856A (ko) 2015-12-18 2016-12-19 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Country Status (18)

Country Link
US (5) US9855238B2 (enExample)
EP (2) EP4218736A3 (enExample)
JP (4) JP2018537513A (enExample)
KR (6) KR20200055154A (enExample)
CN (2) CN108697680A (enExample)
AR (1) AR107143A1 (enExample)
AU (4) AU2016370626B2 (enExample)
BR (1) BR122023026625A2 (enExample)
CA (2) CA3129008A1 (enExample)
ES (1) ES2948444T3 (enExample)
IL (3) IL294736A (enExample)
MX (2) MX394051B (enExample)
NZ (1) NZ744323A (enExample)
PH (1) PH12018501279A1 (enExample)
RU (2) RU2737089C2 (enExample)
SG (1) SG11201805149XA (enExample)
WO (1) WO2017103671A1 (enExample)
ZA (2) ZA201804779B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
ES2727387T3 (es) 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
JP2018524274A (ja) 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
ES2851525T3 (es) 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
EP4218736A3 (en) * 2015-12-18 2023-10-18 Afimmune Limited Compositions comprising 15-hepe
CN113116878A (zh) * 2020-01-10 2021-07-16 南京大学 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11622495B2 (en) 2021-06-01 2023-04-11 Gint Co., Ltd. Method of automatically combining farm vehicle and work machine and farm vehicle
CN113855659B (zh) * 2021-11-24 2022-12-23 中国人民解放军东部战区总医院 12-hepe或其药学上可接受的脂肪酸改善精子发生障碍的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール．ピー．シェーラー コーポレイション 香料を小分けして提供する方法および組成物
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
AU3846801A (en) 2000-02-16 2001-08-27 Brigham & Womens Hospital Aspirin-triggered lipid mediators
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
MXPA03010888A (es) 2001-05-30 2004-02-27 Laxdale Ltd Coenzimas q y acido eicosapentaenoico (epa).
KR20110053281A (ko) 2002-11-22 2011-05-19 니폰스이산가부시키가이샤 산화 안정성이 향상된 이중결합을 가진 유기물을 함유하는 조성물
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
CN101043884A (zh) 2004-07-01 2007-09-26 谢彭斯眼科研究公司 用于治疗眼部疾病和病症的组合物和方法
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
JP5504405B2 (ja) * 2005-06-10 2014-05-28 国立大学法人山口大学 血管病予防に効果を有する食品組成物
WO2008021192A2 (en) 2006-08-08 2008-02-21 Lipomics Technologies, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP2010229099A (ja) * 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd 脂質異常症の改善または治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
JP5313343B2 (ja) * 2009-05-22 2013-10-09 持田製薬株式会社 ω３脂肪酸の自己乳化組成物
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US8936803B2 (en) 2011-10-19 2015-01-20 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
WO2013082265A1 (en) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
SG10201701004RA (en) 2012-01-06 2017-04-27 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
MY189576A (en) * 2012-03-30 2022-02-17 Micelle Biopharma Inc Omega-3 fatty acid ester compositions
ES2606392T3 (es) 2012-04-04 2017-03-23 Pronova Biopharma Norge As Composiciones que comprenden ácidos grasos omega-3 y vitamina D para acné vulgar y/o eccema, y procedimientos y usos de las mismas
EP2858496B9 (en) * 2012-05-10 2023-11-29 Solutex NA LLC Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN111888343A (zh) * 2013-07-18 2020-11-06 持田制药株式会社 ω-3脂肪酸的自乳化组合物
ES2727387T3 (es) * 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
RU2019110980A (ru) * 2014-01-10 2019-08-26 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
JP2018524274A (ja) * 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
EP4218736A3 (en) 2015-12-18 2023-10-18 Afimmune Limited Compositions comprising 15-hepe

Also Published As

Publication number Publication date
IL259846A (en) 2018-07-31
US20190224154A1 (en) 2019-07-25
ES2948444T3 (es) 2023-09-12
JP2020063259A (ja) 2020-04-23
MX2021000773A (es) 2022-07-19
CN108697680A (zh) 2018-10-23
AR107143A1 (es) 2018-03-28
IL294736A (en) 2022-09-01
CA3008774A1 (en) 2017-06-22
CA3129008A1 (en) 2017-06-22
US20180104207A1 (en) 2018-04-19
AU2022291628B2 (en) 2025-04-03
US12274685B2 (en) 2025-04-15
EP4218736A3 (en) 2023-10-18
MX394051B (es) 2025-03-24
US20230106655A1 (en) 2023-04-06
CN113230244A (zh) 2021-08-10
IL318963A (en) 2025-04-01
EP4218736A2 (en) 2023-08-02
RU2018126361A3 (enExample) 2020-01-22
MX2018007390A (es) 2018-11-09
US20170172965A1 (en) 2017-06-22
MX379262B (es) 2025-03-10
BR122023026625A2 (pt) 2024-01-16
JP2023153863A (ja) 2023-10-18
US9855238B2 (en) 2018-01-02
RU2020137883A (ru) 2020-12-03
KR20250130433A (ko) 2025-09-01
BR112018012313A2 (pt) 2018-12-04
JP2021178840A (ja) 2021-11-18
CA3008774C (en) 2021-10-12
KR20200055154A (ko) 2020-05-20
SG11201805149XA (en) 2018-07-30
US20250281442A1 (en) 2025-09-11
NZ783466A (en) 2025-05-30
AU2016370626A1 (en) 2018-08-02
KR20180094516A (ko) 2018-08-23
NZ766360A (en) 2025-05-30
US10231945B2 (en) 2019-03-19
ZA201804779B (en) 2019-09-25
AU2022291628A1 (en) 2023-02-02
AU2020267224B2 (en) 2022-09-29
EP3389647B1 (en) 2023-04-05
ZA202104969B (en) 2023-01-25
KR20240052856A (ko) 2024-04-23
RU2018126361A (ru) 2020-01-22
AU2020267224A1 (en) 2020-12-10
RU2737089C2 (ru) 2020-11-24
AU2016370626B2 (en) 2020-08-20
PH12018501279A1 (en) 2019-01-28
JP2018537513A (ja) 2018-12-20
WO2017103671A1 (en) 2017-06-22
EP3389647A1 (en) 2018-10-24
NZ744323A (en) 2020-08-28
KR20230047501A (ko) 2023-04-07
AU2025201593A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
US12274685B2 (en) Compositions comprising 15-HEPE and methods of using the same
US20210244697A1 (en) Compositions comprising 15-ohepa and methods of using the same
US20190216761A1 (en) Compositions comprising 15-hepe and methods of using the same
BR112018012313B1 (pt) Uso de ácido 15-hidroxieicosapentaenoico ou de um derivado farmaceuticamente aceitável do mesmo para inibir ou aliviar uma doença selecionada dentre artrite, doença de huntington, sensibilidade à insulina comprometida, psoríase, câncer de pele, diferenciação de adipócitos, dor e obesidade

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220314

Application number text: 1020207013456

Filing date: 20200511

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220413

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220422

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221025

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220422

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I